Japan’s general trading houses are steadily becoming a force to be reckoned with in the pharmaceutical industry — and not…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Ashraf Al-Ouf Named President of Bayer Yakuhin and Bayer Holding in Japan
August 8, 2025
-
REGULATORY Public-Private Council WG to Focus on Innovation Evaluation for FY2026 Reform: Official
August 8, 2025
-
BUSINESS Sumitomo Eyes Conditional Nod for iPS Cell Therapy for Parkinson’s in FY2025
August 8, 2025
-
BUSINESS PeptiDream Probes Ex-COO over Unauthorized Provision of Reagents to Academia
August 8, 2025
-
REGULATORY Industry Urges “Objective Review First” for CEA Reform; Payers Push for Expansion
August 7, 2025
-
REGULATORY Welireg, Airwin, Talvey and More Set for NHI Listing; Premiums Wiped Out by “Zero” Rule
August 7, 2025
-
REGULATORY DPO Floats Premium Expansion, Relaxed Criteria towards FY2026 Reform
August 7, 2025
-
REGULATORY Chuikyo Rules Out Long-Term Care Costs in Leqembi CEA, Confirms Price Cut
August 7, 2025
-
REGULATORY Wegovy, Leqvio, Phozevel to Face CEA-Linked Price Cuts in November
August 7, 2025
-
REGULATORY MHLW Device Review Chief Pledges Evidence-Based Approvals amid Diversifying Technologies
August 6, 2025
-
REGULATORY MHLW Trial Office Head Vows to Make Japan a Preferred Site for Clinical Studies
August 5, 2025
-
REGULATORY Wage-Based Price Premiums on Drugs Not an Option, Says MHLW Insurance Chief
August 4, 2025
-
BUSINESS Nihon Chouzai to Go Private through Tender Offer Backed by Advantage Partners
August 1, 2025
-
ORGANIZATION Japan Society Poised to Set Out Criteria to Standardize Regional Formularies, Eyes August Release
July 31, 2025
-
REGULATORY MHLW to Link GS1 and YJ Codes in Public Database, Launch Planned for FY2028
July 30, 2025
-
BUSINESS Gene Therapy Deaths Spur Strategic Rethink among Biotechs, Merck Exec Notes Investor Caution
July 30, 2025
-
REGULATORY Post-Marketing Oversight and Regulatory Reviews Must Work as One, Says New MHLW Safety Chief
July 29, 2025
-
REGULATORY Astellas Employee Did Not Appeal, Prison Sentence Finalized in China
July 29, 2025
-
COMMENTARY Pharmaceutical Policy at a Crossroad amid Political Upheaval in Japan
July 28, 2025
-
REGULATORY MSD’s 21-Valent Pneumococcal Shot Nears Japan Approval; Male Use of Silgard 9 Cleared
July 25, 2025
ページ
A public-private council report outlining industry views on Japan’s drug pricing systems drew little discussion at a meeting of the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
In the complex tapestry of leadership, awareness isn’t just a desirable trait; it’s the bedrock upon which success is built. It’s the lens through which leaders perceive, interpret, and navigate the ever-shifting landscape of their organizations and industries. Without it,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…